Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 ...

The Next Revolution in Cell Therapy Leading Today, Creating Tomorrow Legal Disclaimers To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (“Allogene,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer Dr. David Chang - President and CEO Dr. Zachary Roberts - Executive Vice President, Research and Development and CMO Dr. Eric Schmidt - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Matt Borsch - Goldman Sachs Michael Yee - Jefferies Mark Breidenbach - OpCo Jack Allen - Baird Brian Cheng - JPMorgan John Newm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development Eric Schmidt - CFO Conference Call Participants Jenna Li - Jefferies Tyler Van Buren - Cowen and Company Brian Cheng - JPMorgan Chase & Co. Charles Butler - EF Hutton John Newman - Canaccord Genuity David Dai - SMBC Mark Breidenbach - Oppe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-K _________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38693 _________________________________ Allogen ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Christine Cassiano - CCO David Chang - President and CEO Rafael Amado - EVP, Research & Development and CMO Eric Schmidt - CFO Conference Call Participants Andrea Tan - Goldman Sachs Michael Yee - Jefferies Tyler Van Buren - Cowen Asthika Goonewardene - Truist Raju Prasad - William Blair Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Micha ...